Trial reportPloS one2016
Risk Factors for Long-Term Mortality after Hospitalization for Community-Acquired Pneumonia: A 5-Year Prospective Follow-Up Study.
Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients.The Cochrane database of systematic reviews · 2018Pooled it
- Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial.BMC pulmonary medicine · 2023Trial
- Trial
- Causes and Contributing Factors of In-Hospital and Post-Discharge Mortality Among Patients With Severe Acute Respiratory Infection in Low- and Middle-Income Countries: A Scoping Review.Health science reports · 2026Article
- Health-related quality of life in community-acquired pneumonia: a prospective cohort study.Scientific reports · 2026Article
- Immune risk phenotype and long-term mortality after community-acquired pneumonia in older adults: clinical and immune determinants.Immunity & ageing : I & A · 2026Article
- Transforming post-acute pneumonia management: risk stratification using machine learning.ERJ open research · 2026Article
- Self-organising map clustering identifies high-risk clusters of post-acute mortality in a prospective multicentre study of community-acquired pneumonia.ERJ open research · 2026Article
- Combined Systemic Immune-Inflammation Index-Prognostic Nutritional Index Score in Evaluating the Prognosis of Patients with Severe Community-Acquired Pneumonia.Journal of inflammation research · 2025Article
- Development and validation of mortality risk prediction model for sepsis secondary to pneumonia at intensive care unit admission: a retrospective case-cohort study.Frontiers in medicine · 2025Article
- Steroids in severe community-acquired pneumonia.Breathe (Sheffield, England) · 2024Article
- Does the "Obesity Paradox" Have an Expiration Date? A Retrospective Cohort Study.Journal of clinical medicine · 2023Article
- Predictors of Length of Stay, Rehospitalization and Mortality in Community-Acquired Pneumonia Patients: A Retrospective Cohort Study.Journal of clinical medicine · 2023Article
- Nausea Predicts Bacteremia in Immunocompetent Patients with Pneumococcal Community-Acquired Pneumonia: Secondary Data Analysis from a Prospective Cohort.Journal of clinical medicine · 2023Article
- Acute organ injury and long-term sequelae of severe pneumococcal infections.Pneumonia (Nathan Qld.) · 2023Review
- Factors affecting 90-day mortality in community and hospital acquired pneumonia patients with or without acute kidney injury.African health sciences · 2022Article
- Association of Serum Albumin and Copeptin with Early Clinical Deterioration and Instability in Community-Acquired Pneumonia.Advances in respiratory medicine · 2022Article
- Early post-discharge mortality in CAP: frequency, risk factors and a prediction tool.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Observational
- Age, Pulse, Urea, and Albumin Score: A Tool for Predicting the Short-Term and Long-Term Outcomes of Community-Acquired Pneumonia Patients With Diabetes.Frontiers in endocrinology · 2022Article
- Predicting Prognosis in Internal Medicine: A Short and Long-Term Mortality Comparison Analysis.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContributors to long-term mortality in patients with community-acquired pneumonia (CAP) remain unclear, with little attention paid to pneumonia etiology. We examined long-term survival, causes of death, and risk factors for long-term mortality in adult patients who had been hospitalized for CAP, with emphasis on demographic, clinical, laboratory, and microbiological characteristics.
methodsTwo hundred and sixty-seven consecutive patients admitted in 2008-2011 to a general hospital with CAP were prospectively recruited and followed up. Patients who died during hospital stay were excluded. Demographic, clinical, and laboratory data were collected within 48 hours of admission. Extensive microbiological work-up was performed to establish the etiology of CAP in 63% of patients. Mortality data were obtained from the Norwegian Cause of Death Registry. Cox regression models were used to identify independent risk factors for all-cause mortality.
resultsOf 259 hospital survivors of CAP (median age 66 years), 79 (30.5%) died over a median of 1,804 days (range 1-2,520 days). Cumulative 5-year survival rate was 72.9% (95% CI 67.4-78.4%). Standardized mortality ratio was 2.90 for men and 2.05 for women. The main causes of death were chronic obstructive pulmonary disease (COPD), vascular diseases, and malignancy. Independent risk factors for death were the following (hazard ratio, 95% CI): age (1.83 per decade, 1.47-2.28), cardiovascular disease (2.63, 1.61-4.32), COPD (2.09, 1.27-3.45), immunocompromization (1.98, 1.17-3.37), and low serum albumin level at admission (0.75 per 5 g/L higher, 0.58-0.96), whereas active smoking was protective (0.32, 0.14-0.74); active smokers were younger than non-smokers (P < 0.001). Microbial etiology did not predict mortality.
conclusionsResults largely confirm substantial comorbidity-related 5-year mortality after hospitalization for CAP and the impact of several well-known risk factors for death, and extend previous findings on the prognostic value of serum albumin level at hospital admission. Pneumonia etiology had no prognostic value, but this remains to be substantiated by further studies using extensive diagnostic microbiological methods in the identification of causative agents of CAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.